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A B S T R A C T
Bacterial contamination control in pharmaceutical products is a critical aspect in the field
of drug manufacturing industry due to the encountered risk to the patients’ health and pos-
sibly their life. The application of commercial bacterial identification system is crucial to
identify the type of contamination and its source to anticipate the impact of bioburden on
the products and setting corrective and preventive actions. During the period of one year,
random samples from raw materials and final products were tested according to United States
Pharmacopeia, and those that showed suspect results for specified microorganisms and/
or out-of-specification limits or showed out-of-trend results were subjected to further
identification by using miniaturized biochemical identification system after performing Gram
stain. From the total bacterial isolates of the investigated products, more than 60% were
primarily belonging to Micrococcaceae 16.98% (empty hard gelatin capsules), Enterobacteri-
aceae 18.86% (vaginal cream applicator, plastic caps for bottles, Sorbitol solution, finished
hard gelatin capsule product, topical cream and oral suspension) and Bacillaceae 24.53% (Talc
powder, liquid oral preparation and finished hard gelatin capsule product). Gram Positive
and Negative samples were 56.60% and 41.51% respectively from the total investigated sample
products and materials. Finished pharmaceutical products constituted 53.33% and 68.18%
from Gram-positive and Gram-negative microorganisms respectively. An approach to quan-
titative risk assessment for pharmaceutical products was conducted on selected medicinal
items and showed that Enterobacteriaceae followed by Burkholderiaceae contributed by more
than 80% to the major hazard that could be delivered to patients through drugs. The applied
risk can be used as a milestone for setting goals by pharmaceutical companies to improve
the safety of medicinal products microbiologically and to identify the major sources of the
risk to work on it in order to deliver safe drugs to the customers.
© 2016 Beni-Suef University. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Keywords:
Bacterial contamination
Pharmaceutical product
Biochemical identification
Quantitative risk assessment
Enterobacteriaceae
Burkholderiaceae
* Microbiological Quality Control Department, Hikma Pharma Pharmaceutical Company, P.O. Box 1913, Cairo 11511, Egypt. Fax: +20238331791.
E-mail address: mostafaessameissa@yahoo.com.
http://dx.doi.org/10.1016/j.bjbas.2016.08.005
2314-8535/© 2016 Beni-Suef University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
b en i - s u e f un i v e r s i t y j o u rna l o f b a s i c and a p p l i e d s c i e n c e s 5 ( 2 0 1 6 ) 2 1 7 – 2 3 0
Available online at www.sciencedirect.com
journal homepage: www.elsevier.com/ locate /b jbas
HOSTED BY
ScienceDirect
1. Introduction
Microbial contamination and spoilage cost pharmaceutical com-
panies huge financial loss annually through equipment
malfunction, production stoppage, drug contamination, inves-
tigations and loss of energy. The target of most reputable
pharmaceutical firms today is centered on determining the dif-
ferent sources of contamination (Eissa et al., 2014). The quality
of product is assessed through testing and monitoring of the
environmental conditions and manufacturing activities in the
firms where they are processed, packaged, stored and tested
as well as through sampling and analysis of the finished dosage
forms. Products that are found to be contaminated with mi-
croorganisms are recalled from the market. A product can also
be recalled if there is evidence that a deviation occurred during
its manufacture or distribution, resulting in a possible risk to
public health. Such incidences typically occur in small numbers
of batches. However, if a product is found to be unsafe for con-
tinued marketing, it must be withdrawn completely (Clontz,
2008).
The moisture level available for microbial proliferation de-
termines the type of bacteria that most probably can survive
in the pharmaceutical material. The application of water ac-
tivity (aw) in the pharmaceutical and biopharmaceutical
industries was first addressed in the USP Stimuli to the Revi-
sion Process article, “The Application of Water Activity
Measurement to the Microbiological Attributes Testing of
Nonsterile Over-the-Counter Drug Products,” by Friedel and
Cundell (1998). The USP Chapter <1112>, Application of Water Ac-
tivity Determination to Non sterile Pharmaceutical Products, was
finally made official on August 1, 2006, in USP 29, Supple-
ment 2. Generally, Gram-negative bacilli require relatively higher
moisture contents compared to Gram-positive bacteria as
shown in Fig. 1a.
Another factor that should not be overlooked is the length
of time the bacteria can survive before losing cultivability either
in the product or on the dry surface. Most gram-positive bac-
teria, such as Enterococcus spp. (including Vancomycin resistant
enterococci), Staphylococcus aureus (including MRSA), or Strep-
tococcus pyogenes, survive for months on dry surfaces. Many
gram-negative species, such as Acinetobacter spp., Escherichia coli,
Klebsiella spp., Pseudomonas aeruginosa, Serratia marcescens, or Shi-
gella spp., can also survive for months (Kramer et al., 2006).
Fig. 1b illustrates the possible modes of contamination of either
raw materials or pharmaceutical products.
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Fig. 1 – (a) Water activity (aw) levels required to support bacterial growth (Modified from USP <1112>, 2014a). (b) The major
modes of contamination of pharmaceutical dosage forms and their ingredients (Modified from Kramer et al., 2006).
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Risk based approaches include FMEA (Failure Mode and
Effects Analysis), FTA (Fault Tree Analysis) and HACCP (Hazard
Analysis Critical Control Points); all of them employ a scoring
approach (Frank et al., 2008). At present, no definitive method
exists and the various approaches differ in their process and
the degree of complexity involved. However, the two most com-
monly used approaches appear to be HACCP (which originated
in the food industry) and FMEA (which was developed for the
engineering industry) (Whyte and Eaton, 2004).
The aim of the present study is the identification of bac-
terial population during a period of one year from failed and/
or suspected to be out of limits pharmaceutical materials in
newly established pharmaceutical firm and determining their
distribution in the investigated items at the level of bacterial
genus and species to assess the potential hazard of isolated
bacteria on both patient and product.
2. Materials and methods
Microbial tests of pharmaceutical materials were done using
culture media that passed growth promotion tests according
to USP <61> (2014c) and USP <62> (2014d). Bacterial visualiza-
tion was facilitated using colorless Triphenyltetrazolium
Chloride dye which turns red by viable cells. Negative control
samples were included concurrently with the test.
Bacterial isolates were obtained from microbiology labora-
tory in the quality control departments isolated from the tested
products shown in Tables 1 and 2. The bacterial isolates were
isolated and identified using miniaturized biochemical iden-
tification kits BBL™ Crystal™ enteric/non fermenter (E/NF) and
Gram-positive (GP) Identification System and Gram-stain
reagents purchased from BD (Becton Dickinson Microbiology
Systems, Cockeysville, MD). All the nutrient media and chemi-
cals were purchased from OXOID (Basingstoke, Hampshire) and
Sigma-Aldrich (St. Louis, MO 63103), respectively. The investi-
gated bacteria were identified as described by Ashour et al.
(2011). All media were sterilized by autoclaving in validated
steam sterilizer (FEDEGARI FOB3, Fedegari Autoclavi SpA, SS
235 km 8, 27010 Albuzzano (PV), Italy).
All microbial processing was made under validated and cali-
brated biological safety cabinet (Jouan MSC 9 Class II A2
BioSafety Cabinet, Thermo Fisher Scientific Inc., 81 Wyman
Street, Waltham, MA 02451, USA). Moreover, environmental
monitoring (EM) samples from surfaces and air were taken ac-
cording to Eissa (2014) to ensure appropriate cleaning,
disinfection and aseptic behavior under laminar air flow con-
ditions. Illustrations of generated data and calculations were
performed using Microsoft Office Excel 2007. Pareto charts were
constructed using Minitab® v17.1.0. GraphPad Prism v6.01 for
windows was used for statistical analysis.
3. Theory/Calculation
Quantitative Microbiological Risk Assessment (QMRA) (Haas
et al., 1999) that is applied in food industry has been exten-
sively used to assess microbial hazard based on estimating the
risk from exposure to microorganisms by combining dose–
response information for the infectious agent with information
on the distribution of exposures. However, there is no such risk
analysis on the final medicinal dosage forms in the pharma-
ceutical field. An approach to perform quantitative risk
assessment from final medicinal dosage form delivered to the
Table 1 – Parameters required for interpretation of BId and Preservative Efficacy Test (PET) and microbial limit test of non-
sterile products was performed according to pharmacopeial method (USP <51>, 2014b).
Product Maximum
accepted
bioburden (Vc)
(CFU/g or ml)
Maximum
single dose
(Sd) (g or ml)
Bioburden Change (log10 (Reduction or
Increase from Initial Count)/14 Days)a
Staphylococcus
aureus
Escherichia
coli
Burkholderia
cepacia
Pseudomonas
aeruginosa
Antihypertensive tablet 1000 1 tablet (≈0.4 g) ND ND ND ND
Antimalarial tablet 1000 4 tablets (≈0.8 g) ND ND ND ND
Antihyperlipidemic tablet 1000 4 tablets (≈1.4 g) ND ND ND ND
Anticonvulsant tablet 1000 2 tablets (≈1.2 g) ND ND ND ND
Vitamin C capsule 1000 2 capsule (≈0.5 g) ND ND ND ND
Oral anti-inflammatory suspension 100 ≈60 ml 3.0 ≥−2b ≥−2b ≥−2b
Oral cough syrup 100 ≈15 ml 3.5 ≥−2b ≥−2b ≥−2b
Oral antidiarrheal suspension 100 ≈10 ml 3.0 1.7 3.2 3.5
Oral vit. D + calcium supplement syrup 100 ≈5 ml 4.6 5.1 4.1 4.9
Oral antihistaminic suspension 100 ≈10 ml 0.4 ≥−2b ≥−2b ≥−2b
Oral syrup for common cold 100 ≈15 ml 2.8 ≥−2b ≥−2b ≥−2b
Oral Iron supplement syrup 100 ≈15 ml 3 2.8 3.2 3.6
Topical anti-inflammatory
antimicrobial cream
100 ≈3 g >5.5 >5.5 >5.5 >5.5
ND = Not determined due to lack of sufficient data on these new products, but no proliferation was expected for oral solid dosage forms of
water activity <0.5. So, the assumption at worst case would be that there was no significant microbial reduction from these drugs with time,
provided that the primary packaging material was intact and not damaged.
a The results were used as a primary indicator of microbial count change for other Gram-positive and -negative bacteria until further studies
are completed on other microorganisms and the minimum time (t) before release of the product by company was set to 7 days.
b Microbial count increased from the initial value for the tested Gram-negative rods indicating growth in formulation.
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customer was adopted for pharmaceutical products. As with
the ordinary used risk ranks, when the value of the risk index
(RI) increases, the risk from a particular situation rises. The fol-
lowing simplified equation was adopted:
RI
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Vc = Viable microbial count as total bioburden or specific
microorganism per gm, unit or ml of the product.
Fm = Microbial fraction of certain bacterial family or genus
from total bioburden in a product.
tp = Time required to decrease bioburden from initial to
certain value in pharmacopeial antimicrobial efficacy test
(AET) or vice versa in products that support microbial
proliferation.
Ap = Antimicrobial power of the product due to active com-
ponents, preservatives, water activity,…..etc. measured as
reduction ratio from initial inoculums to the final one after
tp or multiplication power in case of products that support
microbial proliferation.
t = Time required to reduce initial actual product micro-
bial count to single CFU or vice versa in products that
support microbial proliferation.
ID = Infective dose per route of administration and is
affected by patient’s health, immunity, concurrent admin-
istration of other medications and age.
Sd = Maximum single dose can be received by the patient
as determined by product pamphlet.
The current study focused on the risk encountered by oral
route due to lack of sufficiently reliable data for other routes
such as dermal, rectal and vaginal infectious doses. In case of
products that do not support microbial proliferation but do not
significantly decrease the original bioburden with time or the
microorganisms’ loss of viability after a considerably long time
such as many weeks or months especially after release to the
market, the equation may be reduced to accommodate
maximum risk to the following formula:
RI
Log Vc Fm Sd
Log ID
=
⋅ ⋅( ) +( )
+( )
1
1
Equation 2 is suited for products with water activity below
0.5 (tablets, capsules and pills) and contaminated by microor-
ganisms (e.g. spores) that withstand harsh conditions such as
dryness.The accepted normal plating variability of 0.5 log varia-
tion is considered as no change from original count. In the lack
of sufficient data for pathogenicity of each bacterium, group-
ing approach into families and choosing the most significant
organism for each (if present) was adopted.The available results
of antimicrobial power (e.g. pharmacopeial Antimicrobial Effi-
cacy Test (AET)) for products such as liquid and semisolid drugs
– based on USP <51> (2014b) – were used as indicator for Ap per
tp. If ID is removed from equations 1 and 2 then RI will reflect
the final microbial contamination (CFU) received by the final cus-
tomer in one single maximum dose regardless of the possibility
of developing signs of infection. If data of microbial reduction
with time are not available, the risk will be calculated at its worst
case (i.e. highest value) from equation 2. From equations 1 and
2, the calculated cut-off value of RI 1 was selected to declare
that the medicinal dosage form is of low risk but RI ≥1 consti-
tutes high risk to the patient health which becomes more intense
in magnitude as it goes far from the cut-off value and vice versa
as the value goes far below 1 where the product becomes more
safe.The risk was conducted on selected examples of drug prod-
ucts with different bacterial families. In case of products that
support microbial growth and proliferation, the reduction factor
was replaced by the multiplication factor as the risk increases
with time and equation 1 becomes as follows:
RI
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In general, equation 3 was expected to be used less fre-
quently than the previous two equations because any medicinal
products with significant water activity, without any protec-
tive antimicrobial properties and support microbial growth
should not be submitted to the market or must be with-
drawn from distributors because of the health risk they pose.
Even if they were clean microbiologically, they are liable to catch
contamination from patients or their surrounding environ-
ment and eventually get spoiled and become unsafe. In the
absence of information about the infective dose per route of
administration, RI could be replaced by bioburden delivered by
drug to patient index (BId). In such instances, Log (ID+1) would
Table 2 – Infective dose of bacteria as indicated from
scientific and research literatures (João et al., 2012;
Leggett et al., 2012).
Bacterial
Family
Microorganism Minimum
Infective Dose
(number of
infective particles)a
Moraxellaceaeb Acinetobacter
baumannii
1.0 × 106(Oth.)
Bacillaceae Bacillus anthracis 2.0 × 104(Skn.)
Bacillus cereus 1.0 × 106(Ing.), 8.0 × 103 (Inh.)
Paenibacillaceaeb
Burkholderiaceae Burkholderia
pseudomallei
1.0 × 101(Inh.)
Microbacteriaceae 3.6 × 107(Oth.)
Micrococcaceaeb
Pseudomonadaceae Pseudomonas
aeruginosa
1.0 × 103 (Skn), 1.0 × 1010(Ing.)
Enterobacteriaceae Shigella spp. 1.0 × 101(Ing.)
Staphylococcaceae Staphylococcus
aureus
1.0 × 105 (Oth.)
Xanthomonadaceae Stenotrophomonas
maltophilia
1.0 × 106
N.B. In the absence of data on the infective doses (ID) of humans,
those of the experimental animals were used until reliable data on
the infectious doses of humans could be determined. The lowest
ID value was chosen if literatures provide range of values.
a Data available about the infective dose of bacteria per route of ad-
ministration were used as quantitative indicator of the infectivity
for its family.
b No data due to either absence of reliable information from litera-
tures about the infective doses, or microorganisms were found to
be of low or nonclinical significance.
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be removed and the new reduced index will be a measure for
microbiological quality of the product that is delivered to the
final customer regardless of the exposure risk. For bacterial iso-
lates that possess low or no clinical significance (where there
is not any significant data about infectivity), BId measure can
be sought as appropriate indicator for the degree of microbio-
logical quality and compliance of the product. Tables 1 and 2
were used as source of data for BId and RI interpretation on
selected medicinal products. For those microorganisms with
no clinical significance, ID → ∞ theoretically, and hence RI value
would be infinitesimally small. In such cases, BId replaces RI
as a comparison measure between products in terms of mi-
crobiological cleanliness.
4. Results
Marketed final pharmaceutical product dosage forms (about
2090 products/year), accessories and raw materials (275 items/
year) from suppliers were tested for total bioburden and the
presence of specified microorganisms. The total rate of mi-
crobial excursion of the tested subjects was about 2.24%. From
the total bacterial isolates from the investigated products, more
than 60% were primarily belonging to Micrococcaceae 16.98%
(empty hard gelatin capsules), Enterobacteriaceae18.86% (vaginal
cream applicator, plastic caps for bottles, Sorbitol solution, fin-
ished hard gelatin capsule product, topical cream and oral
suspension) and Bacillaceae 24.53% (Talc powder, liquid oral
preparation and finished hard gelatin capsule product). Gram
Positive and Negative samples were 56.60% and 41.51%, re-
spectively from the total investigated sample products and
materials. Finished pharmaceutical products constituted 53.33%
and 68.18% from Gram-positive and Gram-negative microor-
ganisms respectively. A group of not identified bacteria – all
of them belonging to Gram-negative rods and coccobacilli which
were Oxidase and Indole negative – contributed to about 7.55%
of the total investigated samples.
The majority of the tested items either did not show any
growth, characteristic morphology of specific microorganisms
on or in dedicated specific solid or liquid media, Out-Of-
Specification (OOS) and/or Out-of-Trend (OOT) results. Table 3
Table 3 – Bacterial species, their occurrence and the general observed colonial characteristics on general media.
Microorganism Frequency of
Detection
Tested Product General Observed
Colonial Characteristics
Acinetobacter lwoffii 1 Anticonvulsant tablet Small to moderate, entire, convex and colorless
Bacillus megaterium 2 Non-sedating antihistaminic oral suspension Small, wavy, flat and white
Bacillus circulans 1 Talc powder Large, irregular, raised and transparent
Bacillus subtilis 2 Ascorbic acid pellets in capsule Large, wavy, irregular and gray
Brevibacillus brevis 1 Non-sedating antihistaminic oral suspension Large, irregular, wrinkled and white
Burkholderia cepacia 4 Non-sedating antihistaminic oral suspension Moderate to large, irregular, raised and green
Enterobacter cloacae 2 Applicators for vaginal cream and Sorbitol
solution 70%
Small to moderate, round, raised, entire and
white or buff
Unidentified
Gram-Negative
Rods
1 Lactose anhydrous Large, irregular, wavy, wrinkled and white
2 Antitussive oral syrup Small to moderate, entire, convex and creamy
1 Proton pump inhibitor pellets in capsule Moderate, round, entire, smooth, convex and white
Klebsiella pneumoniae
spp. Ozaenae
1 Topical anti-inflammatory antimicrobial
cream
Irregular, raised and light buff
Providencia rustigianii 1 Non-sedating antihistaminic oral suspension Moderate, round, convex, entire and light buff
Pantoea agglomerans 3 Plastic caps, Applicators for vaginal cream and
non-sedating antihistaminic oral suspension
Moderate to large, entire, convex or raised,
round or wavy and light yellowish to buff
Stenotrophomonas
maltophilia
1 Antimalarial tablet Small to moderate, smooth, entire, convex and
transparent
Leifsonia aquaticum 1 Non-sedating antihistaminic oral suspension Small, round, smooth, convex, entire and yellow
Micrococcus luteus 2 Hard gelatin capsule Small to moderate, round, entire, convex and
yellow
Micrococcus lylae 6 Hard gelatin capsule Small to large, round, entire, convex and yellow
Micrococcus spp. 1 Hard gelatin capsule Small to moderate, round, entire, convex and
yellow
Pseudomonas aeruginosa 1 Non-sedating antihistaminic oral suspension Green, large, flat, irregular and smooth
Pseudomonas putida 1 Cetostearyl Alcohol Moderate to large, smooth, entire, convex and
light gray
Shigella spp. 3 Ascorbic acid pellets in capsule and Sorbitol
solution 70%
Small to moderate, round, entire and colorless
to light buff
Staphylococcus aureus 1 Plastic caps Medium to large, circular, smooth, convex and
creamy opaque
Staphylococcus capitis 2 Ascorbic acid pellets in capsule Small, round, entire, convex and white
Staphylococcus epidermidis 1 Hard gelatin capsule Small to moderate, round, entire, convex and
white
Staphylococcus haemolyticus 1 Hard gelatin capsule Fine to small, round, entire, convex and white
Staphylococcus vitulinus 1 Sorbitol solution 70% Large, round, smooth, entire, raised and light
yellow
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shows identified microorganisms, rate of detection, products from
which they were isolated and the colonial morphology on general
media. While Table 4 demonstrates the identification profile of
the bacterial isolates using some biochemical tests and accord-
ingly revealing the common sources of the identified
microorganisms. However, It should be noted that colony mor-
phology was not identical for members of Enterobacteriaceae
family. Contribution of each microorganism from total identi-
fied bacteria is demonstrated in Fig. 2, showing that the greatest
proportions came from the following species: Bacillus circulans
(16.98%), Micrococcus lylae (11.32%), Burkholderia cepacia, miscel-
laneous Gram-negative bacteria (7.55% each), Pantoea agglomerans,
Shigella spp. (5.66% each), Bacillus megaterium, Bacillus subtilis, Mi-
crococcus luteus, Staphylococcus capitis and Enterobacter cloacae (each
3.77%) and the remaining microorganisms about 2%. Fig. 3 dem-
onstrates abundance of bacterial families among studied
products and materials.The high participation of B. circulans came
from a single type of cream product which interestingly pos-
sesses antimicrobial effect and notable antibacterial activity.
Rate of microbiological failure from raw materials and ac-
cessories was 8.00% which is more than five times greater than
that of finished products (1.48%). While Gram-positive bacte-
ria shared almost equal distribution between finished medicinal
products and raw materials/pharmaceutical accessories, 68.18%
of Gram-negative rods were present in the final dosage forms
as illustrated in Fig. 4. Liquid oral dosage form (either syrup or
suspension) followed by empty hard gelatin capsules then solid
dosage forms represented more than 64% of the total investi-
gated subjects, with Gram-negative bacilli more predominant
in the liquid products followed by the solid products while Gram-
positive cocci were the primary contaminants in the empty hard
gelatin capsules (all Micrococcaceae and some of Staphylococcus
spp. are within this item). Investigated oral solid pharmaceuti-
cal products were contaminated by both Gram-positive and
Gram-negative bacteria. This distribution is illustrated in Fig. 5.
Pareto diagrams in Figs. 6 and 7 were used to demonstrate the
major sources of defect, showing that while Gram-positive cocci
contaminated empty hard gelatin capsules primarily, the in-
vestigated liquid medicinal products were the major items
contaminated by Gram-negative bacilli rods. The studied semi-
solid products were contaminated mainly by Gram-positive
spore-formers bacilli. Fig. 8 showed RI values in relation to
product type and bacterial families and demonstrated that En-
terobacteriaceae followed by Burkholderiaceae contributed by more
than 80% of total risk for each product type.
Table 5 demonstrated the microbiological risk associated with
products under investigation and included other medicinal prod-
ucts with the consideration of the potential hazard that could
arise from their contamination with the subsequent conse-
quences on the health of the final customer. Some bacterial
families with BId results only because there is no sufficient in-
formation about infective dose and/or microorganisms
Table 4 – Identified bacteria using miniaturized biochemical identification system and their possible origin.
Microorganism O/I C/G Source
Acinetobacter lwoffii N/N Environment, human, soil, foodstuff, water
Bacillus megaterium P/ND Environment, soil, food
Bacillus circulans P/ND Soil
Bacillus subtilis P/ND
Brevibacillus brevis ND/N P/ND Soil, air, water, decaying matter
Burkholderia cepacia P/N Moist environment, soil, water, plant
Enterobacter cloacae N/N P/ND Soil, water, sewage, food
N/N P/ND
Unidentified Gram-Negative Rods N/N Not applicable
N/N
N/N
Klebsiella pneumoniae spp. Ozaenae N/N Tropics, respiratory-ill populations
Providencia rustigianiia N/N Human feces
Pantoea agglomerans N/N Soil, water
Stenotrophomonas maltophiliab N/N Soil, water, animal
Leifsonia aquaticum N/ND P/ND Water
Micrococcus luteus P/ND P/ND Wide distribution in nature, soil, dust, water, air, skin of human and mammals
Micrococcus lylae P/ND P/ND
P/ND P/ND
Micrococcus spp. P/ND P/ND
Pseudomonas aeruginosa P/N Environment, water, plant
Pseudomonas putida N/N Water, soil
Shigella spp. N/N Human and apes
N/N
Staphylococcus aureus P/P Human, animals
Staphylococcus capitis N/N P/N Human skin
Staphylococcus epidermidis N/ND P/N
Staphylococcus haemolyticus P/ND P/N Human skin, primates and domestic animals
Staphylococcus vitulinus P/ND Food, animals
O = Oxidase. I = Indole. C = Catalase. G = Coagulase. P = Positive. N = Negative. ND = Not determined.
a Supplemental testing was recommended by The Crystal ID system.
b Excursion in total viable aerobic count (TVAC) of newly manufactured lot disappeared after repeated testing of the same batch after two
days.
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Table 5 – Quantitative microbiological risk assessment of selected non sterile pharmaceutical dosage forms with different bacterial families based on their normal
abundance found during a course of one year.
Risk at maximum
level
Microbacteriaceae,
Moraxellaceae
and Paenibacillaceae
Bacillaceae Burkholderiaceae Pseudomonadaceae Enterobacteriaceae Staphylococcaceae Xanthomonadaceae Micrococcaceae
aw ≤ 0.5 and/or the intrinsic product properties did not allow for microbial proliferation at least
Antihypertensive tablet RI 0.33 1.43 0.12 1.81 0.33 0.03
BId 0.93 2.00 1.49 1.21 1.88 1.66 0.18 1.84
Antimalarial tablet RI 0.38 1.72 0.15 2.10 0.39 0.04
BId 1.21 2.30 1.79 1.49 2.18 1.96 0.23 2.14
Antihyperlipidemic tablet RI 0.42 1.95 0.16 2.33 0.44 0.05
BId 1.44 2.54 2.03 1.62 2.42 2.20 0.28 2.38
Anticonvulsant tablet RI 0.41 1.88 0.17 2.27 0.43 0.04
BId 1.38 2.47 1.96 1.67 2.36 2.14 0.27 2.31
Vitamin C capsule RI 0.35 1.52 0.13 1.90 0.35 0.03
BId 1.02 2.09 1.59 1.30 1.98 1.76 0.20 1.93
aw > 0.5 and the product properties allowed for some or all bacterial proliferation due to weak or no antimicrobial propertiesa
Oral anti-inflammatory
suspension
RI >5.10 >0.47 >5.87 0.23 >0.69
BId >5.30 >4.71 >6.11 1.13 >4.12
Oral cough syrup RI >3.95 >0.35 >5.86 0.16 >0.49
BId >4.11 >3.53 >6.11 0.81 >2.94
Oral antihistaminic
suspension
RI >3.61 >0.32 >4.38 0.41 >0.43
BId >3.76 >3.17 >4.56 2.06 >2.60
Oral syrup for common
cold
RI >3.95 >0.35 >5.86 0.19 >0.49
BId >4.11 >3.53 >6.11 0.93 >2.94
aw > 0.5 but the product intrinsic properties inhibited microbial content due to significant antimicrobial properties
Oral antidiarrheal
suspension
RI 0.69 0.06 1.18 0.16 0.08
BId 0.72 0.58 1.23 0.82 0.47
Oral vit. D + calcium
supplement syrup
RI 0.51 0.04 0.54 0.11 0.05
BId 0.52 0.38 0.56 0.53 0.30
Oral Iron supplement
syrup
RI 0.76 0.06 0.98 0.18 0.09
BId 0.79 0.63 1.02 0.89 0.52
Topical anti-inflammatory
antimicrobial cream
RI <0.43b <0.30
BId <1.87b <0.90
a No definite value because microbial population was continuously increasing with exception of Staphylococcaceae until reaching plateau threshold which was affected by several factors.
b Based on the finding of several contaminated batches with Bacillus circulans which showed persistence of low level of this bacteria.
223
b
e
n
i-s
u
e
f
u
n
iv
e
r
s
it
y
jo
u
r
n
a
l
o
f
b
a
s
ic
a
n
d
a
p
p
l
ie
d
s
c
ie
n
c
e
s
5
(2
0
1
6
)
2
1
7
–
2
3
0
Acinetobacter lwoffii
Bacillus megaterium
Bacillus circulans
Bacillus subtilis
Brevibacillus 
brevis
Burkholderia cepacia
Enterobacter cloacae
Unidentified Gram-
Negative Rods
Klebsiella pneumoniae spp. 
Ozaenae
Pantoea agglomerans
Providencia rustigianii
Leifsonia aquaticum
Micrococcus luteus
Micrococcus spp.
Micrococcus 
spp.
Pseudomonas 
aeruginosa
Pseudomonas 
putida Shigella spp.
Staphylococcus capitis
Staphylococcus aureus
Staphylococcus epidermidis
Staphylococcus 
haemolyticus
Staphylococcus vitulinus
Stenotrophomonas 
maltophilia Other 
bacteria
Fig. 2 – Bacteria isolated and identified using BBL™ Crystal™ Identification Systems from various raw materials,
pharmaceutical accessories and medicinal products showing contribution of each bacterial species from the total
suspicious and tested samples. (Figure created using Microsoft Office Excel 2007).
Fig. 3 – Abundance of bacterial families or groups through selected suspect samples of raw materials, pharmaceutical
accessories and final medicinal dosage forms that showed suspect microorganisms and/or out of trends or out of
specification results. Suspect samples were identified using BBL™ Crystal™ Identification Systems. (Graph was generated
using Minitab® v17.1.0).
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Fig. 4 – Relative distribution of the suspect and/or failed items, Gram-positive and -negative between finished medicinal
products and the selected raw pharmaceutical materials and drug accessories. (Figure created using Microsoft Office Excel
2007).
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Fig. 5 – Microbial distribution of Gram-positive cocci and bacilli and Gram-negative bacilli within suspect and/or failed
pharmaceutical materials and dosage forms showing the greatest contribution of bacterial contamination originated from
both liquid finished drugs, empty hard gelatin capsules then solid pharmaceutical dosage forms that accounted for more
than 60% from the total materials under investigation. (Figure created using Microsoft Office Excel 2007).
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belonging to this family are of very low or no known pathoge-
nicity. Bacterial families with no BId values are those for dosage
forms with no sufficient data about microbial behavior into the
product matrix. Products – under category of aw > 0.5 and their
intrinsic properties allowed for some or all bacterial prolifera-
tion due to weak or no antimicrobial properties – were
quarantined or withdrawn from the market after current study
because they comprised high risk drugs that constituted health
hazard as their bioburden increased as a function of time with
theoretically calculated infective RI achieved (i.e. RI ≈ 1) for oral
anti-inflammatory suspension, syrup for common cold, anti-
histaminic suspension and cough syrup with Pseudomonadaceae
and Xanthomonadaceae after 23, 14, 33, 22, 38, 26, 33 and 22 days
including 7 days holding time in the firm before release to the
market provided that the increase in microbial count after 14
days was 100 times the initial bioburden. Relative microbial
Fig. 6 – Pareto chart showing Liquid, solid products and empty hard gelatin capsule, which contributed to more than 64% of
defected items (Upper diagram). Contamination of about 80% of the items by Gram-positive bacilli was centered on liquid
and semisolid products (lower diagram). (Graph was generated using Minitab® v17.1.0).
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abundance (Fm) data were derived from the suspect products
because the remaining majority of passed medicinal drugs did
not show any count either because it was absent, below detec-
tion limits or the count is low in number and there is no
characteristic appearance of specific objectionable microorgan-
isms and pathogens on/in pharmacopeial selective media.
The impact of both type of microorganism and the nature
of pharmaceutical product formulation on RI was studied sta-
tistically using Two-Way ANOVA in Table 6, showing that
bacterial family type has potentially greater effect than the type
of formulation in RI and the main significance came from En-
terobacteriaceae followed by Burkholderiaceae on the risk values.
Fig. 7 – Pareto chart showing Empty hard gelatin capsule, which contributed by more than 73% of defected items
contaminated by Gram-positive cocci (Upper diagram). Liquid and solid products constituted by about 65% of microbial
contamination by Gram-negative bacilli (lower diagram). (Graph was generated using Minitab® v17.1.0).
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5. Discussion
Microbial contamination of pharmaceutical products is one of
the major concerns that annoys regulatory health agencies
around the world, notably FDA, where it was listed among the
top ten reasons for product recalls from the market. In the
present study, about one fourth of the defected items came from
the finished liquid dosage forms. Recalls for the past few years
report that the most commonly detected organisms found in
aqueous formulations are pseudomonads and other Gram-
negative organisms. The safety advisories and product recalls
issued by the FDA Safety Information and Adverse Event Re-
porting System (AERS) included examples of microorganisms
not listed in the compendial monographs. Examples of these
microorganisms were Serratia marcescens, Burkholderia cepacia,
P. aeruginosa, P. fluorescens/putida, Enterobacter cloacae, Klebsiella
aerogenes, S. aureus, Corynebacterium spp., Bacillus cereus and B.
subtilis (Clontz, 2008). Tables 3 and 4 showed that most of the
microbial contaminations were from humans, environment (eg.
air and surfaces) and water. Fig. 2 demonstrated this
contamination–source microbes at species/genus level.
Figs. 3–7 demonstrated the distribution profile of different
types of microorganisms within pharmaceutical items, raw
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Fig. 8 – RI values for clinically significant bacterial families with selected group of medicinal products. (Bar graph generated
by GraphPad Prism v6.01 for Windows).
Table 6 – Regular Two-Way ANOVA conducted for definite RI values generated by GraphPad Prism v6.01 for Windows.
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variation P value P value summary Significant
Dosage Form Factor 12 0.0041 ** Yes
Bacteria Type Factor 76 <0.0001 **** Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Dosage Form Factor 2.7 7 0.39 F (7, 28) = 3.9 P = 0.0041
Bacteria Type Factor 17 4 4.4 F (4, 28) = 44 P < 0.0001
Residual 2.8 28 0.098
F = Distribution of the ratio of two estimates of variance. dfn = Degrees of freedom numerator. MS = Mean Square. SS = Sum of Squares. DF = Degrees
of Freedom. dfd = Degrees of freedom denominator.
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materials and dosage forms. Sutton and Jimenez (2012) showed
similar types of bacterial contamination distributed among
various pharmaceutical articles from FDA recalls, indicating the
seriousness and criticality of the nature and type of micro-
bial contamination on the customers’ health, necessitating
withdrawal of these contaminated articles. Accordingly, such
recurrence stimulated the development of new methods of as-
sessment of the microbiological safety of these products, where
the bioburden distribution and nature were combined with the
type of the product and its manufacturing processing
conditions.
Table 5 showed the cessation of the bioburden content of an-
timalarial tablet product after retest. This special situation of
antimalarial tablet highlighted the problem of the time of test
after manufacturing (TOTAM) because after repeated bioburden
testing after about 2 days the count of Stenotrophomonas
maltophilia decreased from 1550 to <100 CFU/g.This is not strange
in the view of findings of other investigators who showed that
the cultivability of this bacterium from dry environment did not
exceed 48 hours (Lane and Brooke, 2014). So the risk raised here
is the great potential of releasing a non-conforming or out-of-
trend (OOT) finished medicinal product to the market due to
apparently complying results. Hence, the debate about the time
that should elapse after manufacturing the finished products
and before conducting microbiological testing should also be re-
solved.The health regulatory agency should be strict about this
situation and enforce pharmaceutical companies to follow the
rules. Also Table 5 demonstrated RI and BId for those microor-
ganisms with well established ID, while those with no clinical
significance BId only could be demonstrated.This could be con-
firmed by the finding in Fig. 8 where there is little variation on
the effect of the dosage forms on the risk, if compared with
bioburden type that contaminates the products.
PET results of P. aeruginosa were used primarily for
Stenotrophomonas maltophilia in view of relatedness of both mi-
croorganisms (Calza et al., 2003) until completion of AET to
include at least 4 other isolates (in addition to Burkholderia
cepacia) namely: Stenotrophomonas maltophilia, Bacillus circulans,
Leifsonia aquaticum and Micrococcus spp. Another supportive evi-
dence is the results of PET that showed that Gram-negative
rods demonstrated responses similar to the used preserva-
tives in the medicinal products. The preservatives are less
specific than antibiotic in antimicrobial action and this was
illustrated by Vu et al. (2014).Thus, the results of PET for certain
microorganisms can be used to predict the response with
similar organisms. On the other hand, Table 6 showed that RI
is influenced by the nature of microbial contamination more
than the effect of the pharmaceutical product type.
In the absence of data about oral infective route for
Burkholderia spp., inhalation dose was used. This approach was
used until further research can be conducted on the infectiv-
ity, its mechanisms and the dose about this microorganism.
The used dose for the oral route was based on voluntary FDA
recalls for anticavity rinse and mouth wash products from the
market due to contamination with this bacterium (Sutton, 2012)
which indicated that these products produced health hazard
through oral route. The current study used infectious dose of
reference microorganisms for most bacterial families. This
concept has been performed and supported by other research-
ers (Howard et al., 2006).
Finally, the uncertainty analysis was excluded from the risk
equations in order to not complicate the analysis in a manner
that outweighs its value. Moreover, the currently applied risk
index is under review in order to include other parameters that
may lead to refinement of the the RI value. The upper ac-
cepted value for each product category per g or ml is being used
for worst accepted case as an initial measure. However, with
the generation of sufficient data for each product of the newly
established firm, a control chart can be constructed for each
medicinal product with precise control limits which allow for
specific Vc value determination in the risk index.
6. Conclusion
The new methodology – applied in the evaluation of the mi-
crobiological risk assessment for the pharmaceutical products
– has provided advantages as follows: (1) It can replace the con-
ventional qualitative method of microbiological risk analysis that
is based on subjective ranking. (2) It takes into account the dif-
ferent manufacturing variables that affect the finished delivered
product to the consumer. (3) It provides objective method for
numerical evaluation of the current product quality and can
measure the degree of change of this quality when any of the
parameters has been changed. (4) It combines both microbio-
logical quality and quantity effect in the pharmaceutical firm
into one risk assessment value. On the other hand, it high-
lights the gap between the continuously increasing list of
objectionable bugs and available information and literatures
about their infective doses per specific route of administra-
tion. Furthermore, little research work was done on infectious
doses for patients with specific disease conditions or on chronic
use of specific medications that modify immunity and health
states.The relative microbial distribution used in risk value de-
termination is required to be updated annually – to reflect the
recent bioburden distribution profile – by each pharmaceuti-
cal plant in an attempt to achieve better assurance of delivering
microbiologically safe drugs to patients in the community by
monitoring the variation in the value of the risk index.
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